Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer

Table 4

Comparison of the postoperative EORTC-QLQ-C30 scale scores of the studied patients in two different groups.

Complications	DC-CIK group n = 53	Control group n = 53	value
QLQ-C30
Functioning scales
Physical	45.62 ± 5.41	42.28 ± 5.18	0.002
Role	47.21 ± 6.59	44.10 ± 6.08	0.013
Emotional	62.73 ± 7.74)	58.96 ± 6.49	0.008
Social	50.71 ± 5.65	48.14 ± 5.90	0.024
Cognitive	65.36 ± 7.05)	62.67 ± 6.55	0.044
Symptom scales
Appetite loss	40.73 ± 6.15	43.52 ± 7.04	0.032
Constipation	40.07 ± 5.89	43.64 ± 6.35	0.003
Dyspnea	41.34 ± 5.98	44.90 ± 5.09	0.001
Fatigue	40.35 ± 5.26	43.24 ± 6.02	0.010
Nausea and vomiting	21.88 ± 4.48	22.53 ± 4.93	0.479
Pain	23.39 ± 3.75	25.23 ± 3.73	0.013
Sleep disturbance	40.68 ± 6.95	43.68 ± 7.53	0.035

Note. EORTC: European Organization for Research and Treatment of Cancer; DC-CIK: dendritic cell-cytokine-induced killer cells.